Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QSC302246
- Development stage
- Phase 1
- Lead developer
- Galen
01
Overview
QSC302246 is an investigational drug candidate being developed by Galen Limited. It has been evaluated in a Phase I clinical trial in the United Kingdom, which was conducted at Quotient Sciences in Nottingham. Because the sponsor has deferred the publication of the full trial protocol, details regarding the drug's mechanism of action, therapeutic indication, and molecular structure remain proprietary and are not yet publicly available.
Beyond the preview
Go deeper on QSC302246.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QSC302246.